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Introduction
e obvious purpose of any diagnostic measure is 
to obtain an accurate impression of the patient’s 
condition. In case of allergy diagnosis this entails 
the identication of the true culprit allergen while 
avoiding to indict harmless allergens. Among the 
various “mimickers of allergy” [1], protein-linked 
carbohydrates are a prominent and well dened 
cause of false-positive reactions. e following 
chapters will deal with plant/insect fucose-contain-
ing CCDs, how they became accepted as being clin-
ically irrelevant, and how CCD-based false-positive 
results can be avoided. Finally, the possibly more 
serious role of α-1,3-galactose containing GalCDs 
will be discussed. 
History and structures of plant/insect CCDs
More than 30 years ago, Aalberse and co-workers in-
cubated patients’ sera with an unusual array of aller-
gens and supposed allergens (e. g., potato and buck-
wheat). ey observed an almost ubiquitous cross- 
reactivity of some sera [2]. More precisely, these sera 
reacted with extracts from pollens, vegetable foods, 
and – noteworthy – also hymenoptera venoms. e 
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Abstract
A relevant proportion of allergy diagnosis is accom-
plished by in vitro determination of specic im-
munglobulin E (sIgE) to extracts from suspected 
 allergens. Such extracts inevitably contain glycopro-
teins, which may react with patients’ IgE. In the case 
of plant and insect allergens, the relevant epitope 
structure is an α-1,3-fucose on the Asn-linked  sugar 
residue of so-called N-glycans. Due to their wide 
distribution, N-glycans carrying this epitope are 
known as “cross-reactive carbohydrate determi-
nant(s)” (CCD[s]). About 15 years of awareness al-
low the conclusion that anti-CCD IgE does not 
cause noticeable clinical symptoms. In consequence, 
diagnostic results arising from CCD reactivity must 
be rated as false positives. With up to 30 % of CCD 
reactive patients, this can be regarded as a serious 
problem. 
Another cross-reactive carbohydrate determinant 
became notorious as a potential cause of anaphylac-
tic reactions to a recombinant glycoprotein drug 
carrying α-1,3-galactose. is galactose-containing 
determinant (GalCD, galactose containing cross- 
reactive carbohydrate determinant) was supposed 
as a trigger for delayed allergic reactions to red meat 
in several cases. us, α-1,3-galactose may have clin-
ical relevance in certain cases – possibly as a result 
of tick bites. Oen, however, GalCDs probably cause 
false-positive results with milk and meat extracts. 
No clear evidence for the role of other non-human 
carbohydrate structures such as N-glycolylneur-
aminic acid as CCD has been presented so far.
Remedies for sIgE based in vitro diagnosis come 
in the form of non-glycosylated recombinant aller-
gen components or of specic CCD inhibitors. e 
high potential of recombinant allergens is  optimally 
realized in the context of component resolved dia-
gnosis using allergen arrays with more than 100 
components, whereas CCD inhibitors increase the 
specicity of conventional extract-based diagnosis. 
Reagents for the detection and inhibition of CCDs 
from plants and insects have been developed, 
 whereas tools for GalCDs of milk and meat lag be-
hind. 
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Abbreviations
BAT Basophil activation test 
CCD  Cross-reactive carbohydrate 
 determinant
Fuc (F) Fucose
Gal (G) Galactose 




Neu5Gc (Ng) N-glycolylneuraminic acid
NRL Natural rubber latex
sIgE Specic immunglobulin E 
Xyl (X) Xylose 
reactivity of the allergen extracts could be greatly re-
duced by periodate treatment, which destroys (main-
ly) terminal sugars in complex carbohydrates. While 
not absolutely specic, periodate sensitivity is a good 
indication for the carbohydrate nature of an epitope. 
Meanwhile, several reports on cross-reactive IgG 
antibodies appeared. e most relevant was on an 
antiserum against horseradish peroxidase [3]. As-
tonishingly, this serum stained the neuronal chord 
in Drosophila embryos. e authors dened the epi-
tope in horseradish as an Asn-linked oligosaccha-
ride (N-glycan) with xylose and a fucose linked 
α-1,3 to the innermost GlcNAc residue (now called 
MMXF) (Fig. 1). Both elements are foreign to mam-
mals, which explains how this N-glycan can be an 
epitope. A similar structure had been described ear-
lier for pineapple bromelain [4], which is among the 
few plant glycoproteins available in  decent purity 
and quantity. 
e elucidation of the N-glycans of honeybee ven-
om phospholipase revealed core α-1,3-fucose as the 
structural basis for the cross-reactivity between 
 insect and plant allergens [5]. A parallel study ex-
ploited the comparable sensitivity of the fucose 
linkage to acid degradation to substantiate the role 
of this fucose residue. A quarter of 122 insect ven-
om positive patients reacted with glycopeptides iso-
lated from protease-degraded bromelain as shown 
by the ability of these glycopeptides to inhibit the 
binding of IgE to honeybee venom phospholipase 
[6]. is ability was largely abolished when the 
glyco peptides were treated with mild acid just to 
that point when the fucose residues were  essentially 
removed. Apparently, a highly cross-reactive “aller-
genic” structure was detected. In the following 
years, a number of trials to proof its biological sig-
nicance were undertaken.
High specicity and anity of anti-CCD 
antibodies
Chemical deglycosylation is a destructive process of 
limited specicity. us, modications other than 
the one intended may occur. More evidence for the 
role of individual sugar moieties could be provided 
by generating the structure rather than destroying 
it. is was achieved using recombinant, pure xylo-
syl- and α-1,3-fucosyltransferase and N-glycan ac-
ceptors from mammals, which are certainly free of 
the sugar residues under investigation. Soluble 
forms of these two glycosyltransferases were ex-
pressed in Pichia pastoris and used to modify hu-
man transferrin. Before, transferrin was trimmed 
with sialidase and galactosidase to get the so-called 
GnGn glycan structure [7]. us,  glyco-variants of 
transferrin were generated specically containing a 
Fig. 1: Selection of relevant cross-reactive carbohydrate determinants. The 
 glycans are composed of galactose (Gal, A), mannose (Man, M), N-acetyl-
glucosamine (GlcNAc, Gn), fucose, (Fuc, F), xylose (Xyl, X), and/or N-glycolyl-
neuraminic acid (Neu5Gc, Ng). Linkages are to be understood as β, except 
where indicated as α. The abbreviations of structures are according to the 
 proglycan system. Briey, all terminal sugars are listed starting with the one in 
the upper left corner and then moving counter-clockwise. In some cases, the 
linkage of the terminal sugar is unambiguous (e.g., with Man, Xyl, GlcNAc 
 residues), in others the options are specied by superscripts. Further 


































































Allergo J Int 2016; 25: 98–105 99
structural feature that was certainly not present on 
the native transferrin. 
ese neo-glycoproteins were then used to detect 
CCD-specic IgG and IgE in patients’ sera. Among 
the patients with multiple grass sensitization, 24 % 
were positive for α-1,3-fucosylated transferrin with 
or without xylose (MMF3 and MMXF3 glycan 
 moiety), whereas none of these sera clearly reacted 
with the xylosylated transferrin [7, 8]. Remarkably, 
rabbit IgG can contain an antibody fraction  specic 
for xylosylated only (MMX) glycans [7, 9]. 
As a nal characterization of human IgE against 
CCDs, a¦nity-puried anti-CCD IgE and an-
ti-CCD IgG were analyzed for their binding  a¦nity 
to MMF3 and MMXF3 glycans [8]. In great contrast 
to other carbohydrate proteins such as lectins with 
their notoriously low binding a¦nities, the anti- 
CCD antibodies exhibited very high a¦nity. In the 
case of IgE, the dissociation constants were compa-
rable to protein allergens. In the case of IgG, the 
 a¦nity was clearly higher [8]. 
Biological signicance of plant/insect CCDs
e process leading to the clinical symptoms of 
aller gy can be re-enacted by test monitoring the 
 degranulation of basophilic granulocytes either by 
measuring released histamine [10], interleukin 4 
[11], or vesicle specic protein markers [12]. Such 
histamine release tests were performed with  tomato 
β-fructofuranosidase or albumin coupled CCD-
glyco peptides [10, 11] and pointed at biological 
 activity very similar to that of undoubted allergens 
such as Bet v 1. e obvious conclusion was that 
core α-1,3-fucosylated N-glycans are relevant aller-
genic epitopes causing clinical symptoms.
Even earlier, van der Veen and co-workers per-
formed histamine release with peanut extracts and 
sera from peanut allergic patients [13]. With sera 
that were peanut reactive solely on the basis of 
CCDs, degranulation only occurred at concentra-
tions much higher than needed for protein based 
reaction with peanut extract. Due to this result, 
they concluded that CCDs lack biological signi-
cance [13]. 
However, one may challenge this test system for 
two reasons: First, the major peanut allergen Ara h 1 
is mono-glycosylated and thus cannot perform the 
cross-linking of Fcε receptors required for trigger-
ing degranulation. Second, peanut glycoproteins 
contain almost no fucose [14]. Anti-Xyl IgE never 
found above baseline – even in peanut allergic pa-
tients [Eiwegger T, Altmann F, Vienna, Austria; un-
published results]. ough the science of this work 
was built on rather uncertain grounds, the conclu-
sion has prevailed. No clear evidence for CCDs pro-
voking allergic reactions has ever been brought for-
ward. As a possible exception the somewhat special 
case of a tomato allergic patient could be mentioned 
for whom a xylosylated N-glycan appeared to be 
part of a peptide epitope [15]. A large study by 
 Adriano Mari, who tested 1,831 subjects of which 
23 % reacted towards plant protein N-glycans, did 
not provide evidence for relevant CCD-based reac-
tions [16]. Of the CCD-positive individuals, 21 % 
showed but very weak skin reactions when tested 
with horseradish peroxidase, but not with phospho-
lipase A2 or ascorbate oxidase [16]. Given the up to 
eight N-glycosylation sites on peroxidase as op-
posed to one and two on PLA and ascorbate oxidase, 
this result can be taken as a corroboration of the 
concept that it requires multivalent binding of an 
allergen to trigger mast cell degranulation. More-
over, these results conrm the assumption that 
CCDs do not cause notable clinical symptoms. 
Ebo and co-workers came with a di°erent ap-
proach to the same conclusion [1]. Much later, the 
biological signicance of anti-CCD IgE was exam-
ined by a commercial basophil activation test 
(BAT), in which CCDs could in fact lead to baso-
phil activation as indicative of biological e¦cacy 
[12]. As the patients had been carefully diagnosed, 
this positive diagnosis against natural rubber latex 
(NRL) and apple could clearly be rated as false- 
positives.
Still unclear is the reason for this essentially 
complete inability of eliciting manifest allergic 
symptoms. Jin and co-workers speculated on an 
inhibitory role of IgG, as the anti-CCD IgG exhib-
ited a higher a¦nity than IgG against well-known 
protein allergens [8]. It may well be envisaged that 
the inevitably frequent uptake of vegetable food 
(including cereals!) could desensitize against plant 
N-glycans by a mechanism akin sublingual im-
mune therapy. 
It is unknown why certain people develop an-
ti-CCD IgE. A link to hymenoptera stings is oen 
discussed [17], whereas the increased risk for anti- 
CCD IgE development among heavy drinkers sup-
posedly does not explain the whole phenomenon [18]. 
An interesting link to the physiological function of 
IgE may be posed by a study, which found increased 
anti-CCD IgE as a result of parasite infection [19].
False positive diagnosis due to CCDs and 
possible solutions
e percentages of allergic individuals sensitized to 
plant/insect CCDs may be estimated from two large 
studies, where sera were collected rather unbiased 
and in which anti-CCD IgE was found in 23 % [16] 
and 22 % [20] of patient cohorts numbering well 
over 1,000 individuals. In the young adult cohort, 
the prevalence reached 30 % [20]. Based on an ad-
mittedly only semi-quantitative strip test, most of 
the reactions were RAST class 2 or higher [20]. For-
100 Allergo J Int 2016; 25: 98–105
Review Coping with CCDs in allergy diagnosis
tunately for the patients, their anti-CCD IgE does 
not bring them any inconvenience.
Already in 1998, Aalberse stated “ese results 
support the concept that the accuracy of serological 
allergy tests will improve if CCD-related reactivity 
can be avoided” [21]. However it required the fun-
damental study of Mari [16] to anchor the clinical 
insignicance of CCDs in the consciousness of the 
experts. Mari’s conclusions were supported by a 
study on “mimickers of allergy”, which concluded 
“Sensitization to prolin and/or bromelain-type 
CCD, caused by pollen (timothy grass, mugwort) or 
hymenoptera venom allergens, can elicit false-pos-
itive IgE antibodies against natural rubber latex and 
apple“ [1]. 
A particular problem is the assignment of the 
culprit insect in the case of apparent double sensi-
tization against bee and wasp venom, which oen 
is solely based on CCD cross-reactivity and only 
rarely a true double sensitization [22]. Nine years 
later, the idea of the innocence of CCDs consoli-
dated further and Hemmer wrote “For the time 
 being, we appreciate judging these antibodies as 
 clinically insignicant as a useful hypothesis, ...” 
[23]. A consistent diagnosis of vespid venom 
 allergy should eliminate the CCD problem, e. g., 
“by CCD-blocking” [24]. 
Taken together, CCDs found in virtually all plant 
allergen extracts and in all hymenoptera venoms are 
a frequent cause of false-positive diagnostic results 
in extract-based sIgE determinations.
Four possible remedies for the CCD problem: 
1. In vivo testing such as skin-prick test or placebo 
controlled food challenges.
2. Ex vivo testing such as the basophil activation test, 
which, however, is not entirely una°ected by 
CCDs [1].
3. In vitro testing with recombinant allergens. is 
is increasingly done with the label “component 
resolved diagnosis” either in single allergen tests 
or on strips or biochip arrays, the most promi-
nent of which currently is the ImmunoCAP 
ISAC system (Phadia, Uppsala, Sweden) com-
prising 112 components from 51 allergen sourc-
es.  Component resolved allergy diagnosis very 
oen gives a better guidance with regard to the 
steps to be taken as a consequence of a positive 
reaction, e. g., because it helps to unveil the pri-
mary sensitizing agent [25, 26, 27]. Recombinant 
allergens are typically produced in Escherichia 
coli and thus are devoid of any glycosylation. 
erefore, there is no CCD problem anymore – 
in theory? However, the ISAC array contains a 
number of allergen components puried from 
natural ex tracts. Indeed, a recent study revealed 
nPhl p 4, nCyn d 1, nJug r 2, nCry j 1, nCup a 1, 
nOle e 1 and nPla a 1 (the “n” indicating natural 
as opposed to recombinant  array component) as 
being recognized by anti-CCD IgE, whereas 
nGly m 5, nGly m 6, nArt v 1, nAmb a 1, nJug r 1 
and nJug r 3 were not [20]. So, even the Immu-
noCAP ISAC is prone to deliver false positive re-
sults based on CCD-reactive IgE. But for most 
components, the sentence “… yields the impres-
sion of a discrepancy as positive ndings in ex-
tract-based diagnosis were not veried by the 
ISAC results.” [28] will hold true. 
Single allergen ImmunoCAP assays will show the 
same problem with the above mentioned natural 
components. Moreover, with CCD-positive sera, 
ImmunoCAP tends to yield +/- threshold read-
ings for recombinant proteins despite their pro-
duction in bacteria. e astonishing reason is that 
the cellulose sponges do not only consist of cellu-
lose but also of some cotton glycoproteins carry-
ing CCD epitopes [29]. e supplier may mean-
while have overcome this drawback. 
4. In vitro testing with competitive inhibition with 
a specic CCD-inhibitor (Fig. 2). Any plant glyco-
protein carrying an MMXF or MUXF structure 
could be used as inhibitor. e glycoprotein 
should contain several CCD structures to exploit 
the multivalency e°ect and it should be very pure 
to avoid an adverse in¶uence by impurities that 
may have homologies to the allergens to be inves-
tigated. Similarly, the glycoprotein itself must not 
contain (cross-)reactive protein epitopes. is re-
quirement can be met by proteolytic degradation 
of the glycoprotein, purication, and nally cou-
pling of the glycopeptide to an immunologically 
inert carrier.
Fig. 2:  Principle and eect of competitive inhibition of anti-CCD IgE. The left 
cup shows a reaction between a protein allergen and its specic IgE. The 
middle cup was coated with a glycoprotein that cross-reacts with anti-CCD IgE. 
Both samples give positive results. In the right cup, a polyvalent inhibitor (e. g., 
the semisynthetic glycoprotein used by Holzweber and coworkers [20]) was 
added resulting in competitive inhibition with coat allergen for the binding of 
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An example for the use of natural glycoproteins is 
the CCD inhibitor cocktail o°ered by Mediwiss 
Ana lytic GmbH (Moers, Germany). It consists of a 
cocktail of three glycoproteins (bromelain, horse-
radish peroxidase, and ascorbate oxidase) and is 
mixed with twice the volume of serum to give a  total 
inhibitor protein concentration of about 300 µg/mL. 
Concerns about the rather high amount of plant 
protein and about the use of an active protease may 
be expressed. 
An example for a protease treated inhibitor is the 
“proglycan” CCD-blocker (www.proglycan.com) 
consisting of bromelain glycopeptide coupled to hu-
man serum albumin [20]. is semi-synthetic in-
hibitor is added to serum in a volume ratio of 1 : 50 
to arrive at a nal concentration of 20 µg/mL. Ex-
tensive tests were performed with allergen strips 
(Fig. 3), the ImmunoCAP single allergen system, the 
ImmunoCAP ISAC (both Phadia, Uppsala, Sweden), 
and the Immulite 2000 (Siemens Healthcare, Erlan-
gen, Germany) [20]. Generally, CCD inhibition led 
to a vast reduction of the number of positive, recte 
false-positive results in all test systems, even in the 
ISAC system for the reasons detailed above. Unsat-
isfactory results where the reading remained above 
or only slightly below the threshold of 0.35 U/mL 
were notably obtained for honeybee venom and the 
venom component Api m 1 (Tab. 1). 
e positive reaction of Api m 1 in the single 
 allergen test remained an enigma as the same com-
ponent did not show any IgE binding in ISAC, 
which is much more in line with recombinant 
Api m 1 not being glycosylated. Could the cotton 
glycoprotein problem be responsible for such a high 
reading? More interesting is the case of the two in-
sect venom extracts (aka complete allergens), where 
the non-inhibited result did not allow to decide on 
the culprit insect. e CCD-inhibited readings still 
saw honeybee venom as positive, but the di°erence 
to wasp venom now was huge (Tab. 1). e remain-
ing 1.1 U/mL could arise from incomplete inhibi-
tion owed to the fact that bee venom has MMF and 
MMFF structures rather than MUXF (Fig. 1) as 
found on the semi-synthetic CCD-blocker [20]. 
 Given the homology between bee and wasp venom 
proteins, the 1.1 U/mL might also result from 
cross-reactivity of a part of the anti-wasp venom IgE 
population. If this diagnosis was performed to de-
cide on which venom to use for specic immune 
therapy, the result could hardly be clearer. 
is review is not the place to discuss economic 
aspects or the di¦culties of interpreting array data. 
It shall nevertheless be pointed out that combining 
extract-based sIgE determinations with CCD-inhi-







































strip I strip II
strip I strip II
Results for the same patient with CCD-blocker
Results with conventional procedure
Fig. 3: Example of the eect of CCD inhibition. Serum of a 46-year-old male from Carinthia, Austria, was tested 
with custom made multi-allergen strips (Mediwiss Analytics, Moers, Germany) containing one or three  
CCD  reporter bands. Experimental details can be found in [20]. In the presence of inhibitor only allergens with 
 anamnestic substantiation appeared as positive.
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Alpha-1,3-galactose – a mammalian CCD
A decade ago, two at rst independent observa-
tions led to the discovery of yet another cross- 
reactive carbohydrate structure: allergic reactions 
towards a glycoprotein drug and delayed anaphy-
laxis aer meat consumption. Severe, even lethal 
anaphylactic reactions were caused by the then 
novel anti-cancer antibody Cetuximab [30]. It was 
concluded that these reactions were based on 
pre-existing IgE against the alpha-galactose epi-
tope (Gal-α-1,3-Gal-β-1,4-GlcNAc) [30]. While 
antibodies against this epitope prevail in the 
popu lation [31], heavy adverse e°ect against 
Cetuximab were only seen in certain areas of 
 USA’s Midwest (later also Kenya) and the current 
guess for this phenomenon is sensitization by tick 
bites [32].
At the same place and time episodes of meat 
 allergy were observed, which appeared strange as 
the clinical symptoms developed only several 
hours aer the carnal meal and as they sprang up 
without warning and re-appeared unpredictably 
[33]. With the raised awareness due to the Cetuxi-
mab case, IgE to alpha-Gal was identied as the 
likely culprit epitope of meat allergy [32]. Pork kid-
ney turned out as a particularly potent elicitor of 
anaphylactic reactions [34]. ere appears to be a 
correlation between meat allergy and alpha-Gal 
IgE that allows to regard alpha-Gal as a carbo-
hydrate epitope with clinical relevance [34, 35]. It 
should nevertheless be added that alpha-Gal IgE 
can also be found in healthy individuals [Soukop 
K, Altmann F, Hemmer W, Vienna, Austria; un-
published results]. While most people exhibit IgG 
against the alpha-Gal epitope, it may require some 
special trigger to obtain sensitization and IgE pro-
duction [36]. is trigger could come from ticks, 
an idea that is further substantiated by patients’ 
history and tick habitat range in eastern Austria 
[Swoboda I, Vienna, Austria; personal communi-
cation].
It must be stated that the macro-structure of an 
alpha-Gal IgE epitope (e. g., the e°ect of the num-
ber of alpha-Gal residues per glycan or its occur-
rence on O-glycans and glycolipids in addition to 
N-glycans) has not yet been dened [32]. Skin tests 
with an alpha-Gal containing non-allergenic pro-
tein have not yet been performed. e use of Ce-
tuximab and bovine thyroglobin appears as a 
rather awkward approximation to a specic and 
dened tool for anti alpha-Gal-IgE determination 
or inhibition as both are a mixture of various 
structures and both contain N-glycolylneuraminic 
acid, another potential IgE epitope. Neo-glycopro-
teins with various trisaccharides containing α-1,3-
galactose (Dextra Laboratories, Reading, United 
Kingdom) may be useful but have not been tested, 
certainly not in comparison to N-glycans with one 
or two α-1,3-galactose residues (Fig. 1). 
Other potential CCDs
A variety of other non-human carbohydrate deter-
minants could emerge as cross-reactive carbo-
hydrate determinants. But so far, neither N-glycolyl-
neuraminic acid (as found on Cetuximab [37], nor 
the Lewis a epitope found on plant glycoproteins, 
nor arabinogalactans on allergens [38] have as yet 
been described as IgE epitopes, even less as cross- 
reactive carbohydrate determinants. ß-Arabinoses 
on weed pollen allergens can bind IgE but do not 
seem to be widely occurring [38].
Conclusion
Specicity of diagnostic tests is a big issue. us, it 
is surprising that in the case of CCDs the maxi-
mum achievement so far are products for the de-
tection of anti-CCD IgE. Obviously, there is little 
pressure to react. Indeed, in the case of single 
 allergen testing both physician and patient are 
contented if the four or ve allergens tested pro-
vide positive results. e physician was – appar-
ently – right and the patient is impressed by her/
his uncanny instinct. Should the “allergen” later 
on never cause any discomfort it is taken by the 
Tab. 1: Serum of a 46-year-old male analyzed by various methods 
with and without application of a CCD inhibitor (Extracted from 
[20]).* 




Bee venom 28.5 1.1 drastic reduction, still pos.
Yellow jacket venom 28.5 18.3 clearly positive
CAP with components
rApi m1 1.63 0.31 conflict with ISAC
rVes v1 11.8 9.7 clearly positive
rVes v5 48.7  44.6 clearly positive
ISAC (selected results) ISAC n ISAC i  
rApi m1  0 0 clearly negative
rPol d5 1.0 1.5 clearly positive
rVes v5 6.2 8.9 clearly positive
*Sera were tested by the either the conventional ImmunoCAP test (Phadia, Uppsala, Sweden) or the 
 multi-component array ImmunCAP ISAC (Phadia, Uppsala, Sweden) either in the normal format  
(CAP n, ISAC n) or with CCD-inhibitor (CAP i, ISAC i). 
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patient as a conrmation of the treatment’s quali-
ty. With multi-allergen tests, however, the need for 
a rational management of the CCD issue arose. 
 Hopefully, this review facilitates dealing with 
CCD-based false polysensitization.
Dr. Friedrich Altmann 
Department of Chemistry
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